On November 16, 2024, Giles Lomax, CEO of SMA UK, alongside senior leadership representatives, visited Biogen’s UK Head Office in Maidenhead. The visit offered a valuable opportunity to engage with the entire Biogen team, including those focused on SMA and other disease areas, raising awareness of SMA and emphasizing the importance of treatment within the UK community.

During the presentation, the SMA UK team outlined their ongoing efforts, which include providing grants to meet various needs such as access to treatments and funding for wheelchairs. They also shared SMA UK’s four-year strategy and discussed current and future initiatives, including the Resonate events, the SMA Care project, and the upcoming 2025 conference.

The afternoon session gathered the Biogen SMA team to gain insights into SMA UK’s advocacy work. Attendees learned about the community’s needs regarding current and future treatments. Key topics discussed were the need for more equitable access to high-quality care across the UK, improved communication about clinical trials, and making access to trials easier.

At the conclusion of the day, the Biogen team reflected, stating, “This was a truly inspiring day and reminds us why we do the work we do.”